Home > Back to Publisher > Report Information

Emerging Markets Clinical Development Series Africa

Cutting Edge Information
November 1, 2010
117 Pages - SKU: CIGQ6057025

Abstract Table of Contents Related Reports

Countries covered: Africa

Despite maintaining regional offices within Africa, many major drug and device manufacturers frequently overlook the continent when sponsoring clinical studies. Cultural barriers, political upheaval and uneven infrastructure are certainly causes for the lack of interest. But Africa offers tremendous expertise and opportunity for drug and device companies looking for cost-effective study sites and appropriate patient populations.

As challenging as Africa may seem, drug companies have made commitments to improve healthcare across the continent, and these companies’ clinical development strategies go hand-in-hand with that improvement. In coming years, the drug and device industries will greatly expand their clinical development presence in Africa, mainly in South Africa and a select few North African nations. Make sure that your clinical strategy team has all the knowledge available about the growth opportunities in these countries.

Africa presents a unique profile that interests many multinational life sciences companies. If the following benefits outweigh the challenges for a clinical team — as they often do — trial sponsors will find value in Africa:

Patient access: Of all emerging regions, Africa has arguably the least access to quality care, ensuring a steady stream of dedicated patients to fill trial enrollments. In addition, the most advanced nations offer highly diverse patient populations that will translate well for submissions in the US and EU.
Location: Many major European companies are located just across the Mediterranean from North Africa, making travel and communication easier than in Latin America, for example. For American companies, Africa is much closer than Asia.
Underutilization: Though trial saturation is not a concern in emerging markets yet, Africa is the least saturated. Companies that establish clinical operations bases now will be ahead of the pack when more of the industry turns to Africa

Clinical Development in Africa: Understand the Risks but Do Not Overlook Africa’s Potential: Scoring Africa; Study Methodology; Participating Companies; Report Layout; Profile Layout; Running Trials in Africa: Key Recommendations for Success
South Africa: Clinical Environment Overview; Clinical Development Strategy; Clinical Development Profiles
Working in Emerging North African Countries: Clinical Development Profiles
CHARTS AND GRAPHICS
Executive Summary
Scoring Africa: Figure E.1: African Population Compared to US and 5 EU; Figure E.2: Number of Studies Registered by Region; Figure E.3: Number of Studies Registered in Select African Countries; Figure E.4: Scoring Africa: Patient Access; Figure E.5: Scoring Africa: Patient Retention; Figure E.6: Scoring Africa: Regulatory Environment; Figure E.7: Scoring Africa: Intellectual Property Laws/Practice; Figure E.8: Scoring Africa: Cultural Environment; Figure E.9: Scoring Africa: Communication/Language; Figure E.10: Scoring Africa: Trial Technology Infrastructure; Figure E.11: Scoring Africa: Supply Chain Management; Figure E.12: Scoring Africa: Available Knowledge Base; Figure E.13: Scoring Africa: Data Standards; Figure E.14: Scoring Africa: Investigator Standards; Figure E.15: Scoring Africa: Site Management Standards; Figure E.16: Average Percentage of Budget Saved by Running a Site in Africa; Figure E.17: Average Percentage of Time Saved by Running a Site in Africa; Figure E.18: Scoring Africa: Anticipated Cost
South Africa
Clinical Environment Overview: Table 1.1: Key Demographic Figures for South Africa (2010); Figure 1.1: Change in Life Expectancy (1960-2050); Table 1.2: Top 10 Causes of Death in South Africa (2002); Figure 1.2: Ethnicities in South Africa (2000 Census); Table 1.3: Key Economic Figures (2009); Table 1.4: Key Healthcare System Figures (2005-2009); Figure 1.3: Country’s Healthcare Spending as a Percent of GDP (2006); Figure 1.4: Health Spending by Sector (2005)
Clinical Development Strategy: Figure 1.5: Percentage of Budget Saved by Running a Trial in South Africa; Figure 1.6: Percentage of Time Saved by Running a Trial in South Africa; Figure 1.7: Assigning Clinical Development Responsibilities for South Africa; Figure 1.9: Scoring South Africa: Clinical Environment Scores; Figure 1.10: Importance of Factors that Impact Clinical Trial Environment for Companies Operating in South Africa; Figure 1.11: Importance of Factors that Impact Trial Operations for Companies Operating in South Africa; Figure 1.12: Scoring South Africa: Trial Operations Scores
Clinical Development Profiles: Figure 1.13: Profile 1: Company Background; Figure 1.14: Profile 1: Experience in Africa; Figure 1.15: Profile 1: Clinical Strategy in South Africa; Figure 1.16: Profile 1: Scorecard for South Africa; Figure 1.17: Profile 2: Company Background; Figure 1.18: Profile 2: Experience in Africa; Figure 1.19: Profile 2: Clinical Strategy in South Africa; Figure 1.20: Profile 2: Scorecard for South Africa; Figure 1.21: Profile 3: Company Background; Figure 1.22: Profile 3: Experience in Africa; Figure 1.23: Profile 3: Clinical Strategy in South Africa; Figure 1.24: Profile 3: Scorecard for South Africa; Figure 1.25: Profile 4: Company Background; Figure 1.26: Profile 4: Experience in Africa; Figure 1.27: Profile 4: Clinical Strategy in South Africa; Figure 1.28: Profile 4: Scorecard for South Africa; Figure 1.29: Profile 5: Company Background; Figure 1.30: Profile 5: Experience in Africa; Figure 1.31: Profile 5: Clinical Strategy in South Africa; Figure 1.32: Profile 5: Scorecard for South Africa
Working in Emerging North African Countries
Clinical Development Profiles: Figure 2.1: Profile 6: Company Background; Figure 2.2: Profile 6: Experience in Africa; Figure 2.3: Profile 6: Clinical Strategy in Egypt; Figure 2.4: Profile 6: Scorecard for Egypt; Figure 2.5: Profile 7: Company Background; Figure 2.6: Profile 7: Experience in Africa; Figure 2.7: Profile 7: Clinical Strategy in Morocco; Figure 2.8: Profile 7: Scorecard for Morocco; Figure 2.9: Profile 8: Company Background; Figure 2.10: Profile 8: Experience in Africa; Figure 2.11: Profile 8: Clinical Strategy in Tunisia; Figure 2.12: Profile 8: Scorecard for Tunisia

More Africa Reports

D&B Country RiskLine Report: Zimbabwe by Dun & Bradstreet Inc.
This D&B Country RiskLine Report will help you analyze the risks, opportunities and likely payment delays when doing business in this country. It includes ...

D&B Country RiskLine Report: Zambia by Dun & Bradstreet Inc.
This D&B Country RiskLine Report will help you analyze the risks, opportunities and likely payment delays when doing business in this country. It includes ...

D&B Country RiskLine Report: Uganda by Dun & Bradstreet Inc.
This D&B Country RiskLine Report will help you analyze the risks, opportunities and likely payment delays when doing business in this country. It includes ...

D&B Country RiskLine Report: Tunisia by Dun & Bradstreet Inc.
This D&B Country RiskLine Report will help you analyze the risks, opportunities and likely payment delays when doing business in this country. It includes ...

D&B Country RiskLine Report: Sudan by Dun & Bradstreet Inc.
This D&B Country RiskLine Report will help you analyze the risks, opportunities and likely payment delays when doing business in this country. It includes ...

See all reports like this >>

Emerging Markets Clinical Development Series Africa

Share this report

Other tasks

Research Assistance

Related Markets

Research & Development Reports

Free Alert Me service